12 results about "Nicotine replacements" patented technology

Tobacco products comprising smokeless tobacco products and active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel are disclosed. Nicotine replacement therapies comprising active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel. The active ingredient may reduce or eliminate sensory irritation arising due to use of the product. Analgesic compositions comprising active ingredients. Methods of reducing taste and sensory irritation by employing an active ingredient.

Tobacco products comprising smokeless tobacco products and active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel are disclosed. Nicotine replacement therapies comprising active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel. The active ingredient may reduce or eliminate sensory irritation arising due to use of the product. Analgesic compositions comprising active ingredients. Methods of reducing taste and sensory irritation by employing an active ingredient.

The invention discloses a composite probiotic preparation capable of improving sensitivity of low-dose nicotine and reducing usage amount of nicotine, and belongs to the crossing field of microbial technology and biological medicine. The compound probiotic preparation only improves the sensitivity of mice to low-concentration nicotine, does not improve the preference of the mice to the existing preference concentration, prevents aggravated smoking addiction, enables individuals to reach the satisfaction of smoking at ordinary times under the condition of low dosage of nicotine, and has the advantages of being simple in preparation process, low in cost and the like. The formulations may be used in combination with products in nicotine replacement therapy or alone. The compound probiotic preparation disclosed by the invention can be used for preparing functional foods, health-care products and medicines capable of improving the sensitivity of the low-concentration nicotine, and has a very wide application prospect.

Provided herein are methods of combined treatments using bupropion and / or its metabolites and zonisamide or other similar anticonvulsants or GABAergic agents, optionally in further combination with one or more nicotine replacement or substitution products, for promoting smoking cessation, reducing craving for combustible tobacco products, treating dependency, addiction, or withdrawal associated with combustible tobacco products, and / or for facilitating a smoker to switch from combustible tobacco products to a nicotine replacement or substitution product such as e-cigarettes.

The present application relates to the technical field of electronic atomization, and specifically relates to a nicotine replacement liquid preparation, and a preparation method therefor and the use thereof. In the nicotine replacement liquid preparation provided in the present application, the raw material components of the nicotine replacement liquid preparation comprise an additive capable of simulating the throat-hit sensation of nicotine, an additive capable of simulating the head-rush sensation of nicotine, and an atomization solvent. The additive capable of simulating the throat-hit sensation of nicotine is selected from at least one of piperine and 6-methylnicotine; and the additive capable of simulating the head-rush sensation of nicotine is selected from at least one of cytisine, magnolol and 6-methylnicotine. The nicotine replacement liquid preparation of the present application simulates the head-rush sensation and throat-hit sensation brought about by nicotine, enhances the head-rush sensation and throat-hit sensation of a nicotine-free atomization preparation, and improves the sense of satisfaction of a user, thereby achieving the aim of relieving addiction physiologically. Moreover, the toxicity and addictiveness of the nicotine replacement liquid preparation are both much lower than nicotine, such that damages to health can be reduced.

The invention discloses nicotine jelly and a preparation method thereof. The nicotine jelly comprises a nicotine source and a jelly substrate, wherein the nicotine source is dispersed in the jelly substrate; wherein the nicotine source comprises a non-embedded nicotine source and a nicotine source embedded in the microcapsule particles. The nicotine jelly can adapt to different release scenes by adjusting the embedding proportion, safety and portability are both considered, and an innovative solution is provided for nicotine replacement therapy.

The invention provides a nicotine replacement compound, a water-soluble nicotine-free preparation, a preparation method of the water-soluble nicotine-free preparation and an aerosol system. The nicotine replacement compound disclosed by the invention is prepared from the following components: 6-methyl nicotine, 5-ethynyl nicotine and ABT-418, so that not only can sensory experience similar to that of nicotine be provided for smoking quitters be provided, but also addiction and health risk caused by nicotine can be avoided. By simulating the physiological and psychological effects of nicotine, a smoker is helped to gradually reduce the dependence on nicotine. The invention also provides a water-soluble nicotine-free formulation, a preparation method thereof and an aerosol system.

This application belongs to the field of food or pharmaceutical technology, specifically relating to a lozenge and its preparation method. The lozenge includes a granular composition comprising the following components: an active substance, a cationic resin, cationic salt sustained-release granules, and a filler; wherein the active substance includes at least one of the following: nicotine or a nicotine derivative. This solution incorporates cationic salt sustained-release granules into the lozenge, which not only effectively prevents the rapid dissolution of the cationic salt, allowing it to maintain an effective concentration in the oral cavity for a prolonged period, thus facilitating sufficient contact with the cationic resin to ensure nicotine replacement, but also regulates the release rate of the cationic salt, thereby regulating the nicotine replacement rate.

The present disclosure relates to methods incorporating the use of a biomarker (CEVal) for assessing compliance with a smoking cessation program, for example, a smoking cessation program which involves subjects switching from conventional cigarettes to a hybrid device, an e-cigarette and / or a tobacco heating product, a smoking cessation program involving the use of nicotine replacement therapy, a smoking cessation program involving lifestyle choices or therapy, or a combination thereof.

A composition intended to be employed for therapeutic purposes incorporates an active ingredient (e.g., a source of nicotine) and at a non-active ingredient that is carried by a porous substrate. The non-active ingredient can be a substance that has the capability of affecting the pH of the biological system to which it is applied (e.g., basic substance and / or buffering agent is sorbed onto the porous carrier, so as to be in intimate contact with that carrier). Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) and nicotine polacrilex. The basic substance can be sodium carbonate, and the porous substrate can be microcrystalline cellulose. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and can be used as a nicotine replacement therapy.

A composition intended to be employed for therapeutic purposes incorporates an active ingredient (e.g., a source of nicotine) and at a non-active ingredient that is carried by a porous substrate. The non-active ingredient can be a substance that has the capability of affecting the pH of the biological system to which it is applied (e.g., basic substance and / or buffering agent is sorbed onto the porous carrier, so as to be in intimate contact with that carrier). Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) and nicotine polacrilex. The basic substance can be sodium carbonate, and the porous substrate can be microcrystalline cellulose. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and can be used as a nicotine replacement therapy.

A device for providing nicotine replacement therapy may be provided. The device may comprise a processor. The processor may be configured to perform one or more actions. A cessation program for a user may be determined. A program intervention event based on a phase of the cessation program may be determined. A marker associated with the user may be determined. A modification to the cessation program may be determined based on the program intervention event.